Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Carrie Carda, national medical director for 10X health, a company that sells peptides, says
Receptor Pathway Comparison This dual incretin research peptide shares the same receptor targets (GLP-1R + GIPR) as Tirzepatide (LY3298176), the FDA-approved twincretin compound studied extensively in metabolic research
Since it also bypasses your digestive system, its another reliable choice for women on GLP-1 medications
[1] [2] This trial enrolled adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity the primary cohort was largely without type 2 diabetes and assessed multiple doses of retatrutide against placebo over 24 weeks, with an extension to 48 weeks
For a 70 kg individual, this translates to approximately 1.75-28 mg per dose, though standard therapeutic protocols use significantly lower daily doses
The program delivers measurable improvements supported by research, not marketing claims
